Biomarkers for risk assessment in colorectal cancer patients
Innovative Products and Technologies
Technology Offer
Biomarkers for risk assessment in colorectal cancer patients
- RAMOT at Tel Aviv University Ltd.
- From Israel
- Responsive
- Innovative Products and Technologies
Summary of the technology
Mortalin/GRP75, a ubiquitous mitochondrial chaperone related to the cytosolic heat shock protein 70 (HSP70), was quantified for the first time in sera of colorectal cancer patients. The significance of mortalin in blood to the survival prospects of colorectal cancer patients was demonstrated, concurrence with documented extracellular soluble HSP70 (sHSP70).
Circulating Mortalin and extracellular soluble HSP70 (sHSP70) are independent risk factors for short survival of the patients. Moreover, concurrence of high circulating HSP70 and mortalin levels adds a high prognostic value to the TNM stage (TNM Classification of Malignant Tumors) and will identify colorectal cancer patients at high risk of poor survival.
Project ID : 5-2012-401
Details of the Technology Offer
Technology
We have developed an ELISA-based immunoassay that measures the levels of two proteins in the blood, Mortalin/GRP75 and HSP70, identifying colorectal cancer patients at high risk of poor survival.
Mortalin/GRP75, is a ubiquitous mitochondrial chaperone related to the cytosolic heat shock protein 70 (HSP70). We have conducted a clinical trial, collecting and analyzing blood samples from 175 colorectal cancer patients. We demonstrated, for the first time, the presence of circulating mortalin in blood of cancer patients. We have found that circulating Mortalin and extracellular soluble HSP70 (sHSP70) are independent risk factors for poor survival of the patients. Taken together, analysis of these two biomarkers provides a highly significant prognostic value to identify colorectal cancer patients at high risk of poor survival.
Experiment highlights:
- Cox regression analysis indicated that high mortalin (>60ng/ml) is a risk factor for poor survival.
- Serum levels of sHSP70 and mortalin in patients were independent variables.
- Concurrence of high sHSP70 and mortalin was associated with rapid disease progression (HR=4, 2.04-8.45, P